Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Kuromanin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.96 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.50 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | CD38 | P28907 | 2/20 | 0.96 |
| ▸ | F2 | P00734 | 2/20 | 0.85 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | P4HB | P07237 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kuromanin SCHEMBL3765133 | 1.00 | DPP4 (0.96) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL29762023 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL440823 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL29377806 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL158216 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL29349461 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL5509009 | 0.99 | CD38 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL316825 | 0.99 | DPP4 (0.98) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL5510421 | 0.98 | CD38 (0.96) | DPP4CD38F2SNCAGLO1 | |
| Kuromanin SCHEMBL1096430 | 0.98 | CD38 (1.00) | DPP4CD38F2SNCAGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313675-A1 | Anti-Aging Telomere-Strengthening NAD+ Sirtuin Dietary Supplement Composition | SHULTZ LARRY (US) | 2022-10-06 | — | — | US | claimed |
| WO-2020263075-A1 | A FORMULATION THAT REDUCES OXIDATIVE STRESS | UNIVERSITI KEBANGSAAN MALAYSIA (UKM) (MY) | 2020-12-30 | — | — | WO | claimed |
| US-20250114419-A1 | INTESTINAL HEALTH PROMOTING COMPOSITIONS | NSE PRODUCTS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20240058408-A1 | COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION CONTAINING GINSENG BERRY EXTRACT | HOLISTIC BIO CO., LTD. (KR) | 2024-02-22 | — | — | US | disclosed |
| US-20230149309-A1 | COMPOSITION COMPRISING ANTIMICROBIAL AGENT AND ITS USES | SHARED VISION TECHNOLOGY LTD. (IE) | 2023-05-18 | — | — | US | disclosed |
| CN-110636760-B | Composition for promoting intestinal health | NSE产品公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2023286950-A1 | COMPOSITION CONTAINING GINSENG BERRY EXTRACT AND LUTEIN FOR PREVENTING OR TREATING MACULAR DEGENERATION | 주식회사 홀리스틱바이오 | 2023-01-19 | — | — | WO | disclosed |
| US-20220322719-A1 | INTESTINAL HEALTH PROMOTING COMPOSITIONS | NSE PRODUCTS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220313675-A1 | Anti-Aging Telomere-Strengthening NAD+ Sirtuin Dietary Supplement Composition | SHULTZ LARRY (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2022145813-A1 | COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION CONTAINING GINSENG BERRY EXTRACT | 주식회사 홀리스틱바이오 | 2022-07-07 | — | — | WO | disclosed |
| EP-2881155-B1 | Pressurised low polarity water extraction apparatus and methods of use | SENSIENT NATURAL EXTRACTION INC (CA) | 2022-04-06 | — | — | EP | disclosed |
| WO-2012021401-A1 | COMPOSITIONS COMPRISING A POLYPEPTIDE HAVING CELLULOLYTIC ENHANCING ACTIVITY AND A BICYCLIC COMPOUND AND USES THEREOF | NOVOZYMES, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20100316743-A1 | INHIBITION OF THE FORMATION OF AGEs | BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S. (FR) | 2010-12-16 | — | — | US | disclosed |
| US-7807422-B2 | set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100196331-A1 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS | JOHNSON LANNY L | 2010-08-05 | — | — | US | disclosed |
| US-20090239272-A1 | set of genes which encodes for enzymes which can convert substrates belonging to the general category of phenylpropanoids and result in the production of flavanones; without the need for chemical conversion | KOFFAS MATTHEOS | 2009-09-24 | — | — | US | disclosed |
| US-7338791-B2 | Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1778850-A2 | PRODUCTION OF FLAVONOIDS BY RECOMBINANT MICROORGANISMS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060019334-A1 | Introducing the set of genes into a heterologous host cell, allowing growth of the cells in a suitable medium such that the expression of the genes results in production of enzymes; culturing the cell under conditions permitting the synthesis of the flavonoid by the cells; isolating s flavonoids | NATIONAL SCIENCE FOUNDATION | 2006-01-26 | — | — | US | disclosed |
| WO-2006010117-A2 | PRODUCTION OF FLAVONOIDS BY RECOMBINANT MICROORGANISMS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316743-A1 | INHIBITION OF THE FORMATION OF AGEs | AGER, GLA, S100A6 | DPP4 192/4885GAA 107/4885ADRA2C 3397/4885 |
| US-20100196331-A1 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS | SLC2A1, SLC2A2, SLC2A8 | DPP4 275/4885GAA 1148/4885ADRA2C 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.